M
Makoto Maemondo
Researcher at Iwate Medical University
Publications - 178
Citations - 12919
Makoto Maemondo is an academic researcher from Iwate Medical University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 39, co-authored 160 publications receiving 11386 citations. Previous affiliations of Makoto Maemondo include Osaka University & Tohoku University.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Takashi Seto,Terufumi Kato,Makoto Nishio,Koichi Goto,Shinji Atagi,Yukio Hosomi,Noboru Yamamoto,Toyoaki Hida,Makoto Maemondo,Kazuhiko Nakagawa,Seisuke Nagase,Isamu Okamoto,Takeharu Yamanaka,Kosei Tajima,Ryosuke Harada,Masahiro Fukuoka,Nobuyuki Yamamoto +16 more
TL;DR: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC and serious adverse events occurred at a similar frequency in both groups.
Journal ArticleDOI
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto,Katsuyuki Kiura,Makoto Nishio,Kazuhiko Nakagawa,Makoto Maemondo,Akira Inoue,Toyoaki Hida,Nobuyuki Yamamoto,Hiroshige Yoshioka,Masao Harada,Yuichiro Ohe,Naoyuki Nogami,Kengo Takeuchi,Tadashi Shimada,Tomohiro Tanaka,Tomohide Tamura +15 more
TL;DR: CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC, and the study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.
Journal ArticleDOI
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Akira Inoue,Takuji Suzuki,Tatsuro Fukuhara,Makoto Maemondo,Yuichiro Kimura,Naoto Morikawa,Hiroshi Watanabe,Yasuo Saijo,Toshihiro Nukiwa +8 more
TL;DR: Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity, and a subsequent randomized trial comparing gefITinib with standard chemotherapy is warranted.
Journal ArticleDOI
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Akira Inoue,Kazuhiko Kobayashi,Makoto Maemondo,Shunichi Sugawara,Satoshi Oizumi,Hiroaki Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,H. Hirano,Kozo Yoshimori,Toshiyuki Harada,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +18 more
TL;DR: Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended.